India's Emcure Pharma gains on partnership with Novo Nordisk
10/11/2025 06:26
** Shares of Emcure Pharmaceuticals EMCU.NS jump 7% to 1455 rupees, highest since August 28 ** Marks biggest intraday percentage rise since October 6 ** Novo Nordisk NOVOb.CO has partnered with Emcure to exclusively distribute and market weight-loss drug Poviztra semaglutide injection in the country ** More than 314,815 shares change hands, 2.5x of 30-day avg ** EMCU rated "strong buy" by 6 analysts on average; median target price is 1,630 rupees – data compiled by LSEG ** Stock up 0.5% YTD (Reporting by Rudra Pratap Singh in Bengaluru) ((rudrapratap.singh@thomsonreuters.com))
Recent news on Emcure Pharmaceuticals
See all newsIndia's Emcure Pharma rises on Poviztra approval, Motilal initiation with 'buy'
Brief: Emcure Pharmaceuticals Ltd To Expand Use Of Poviztra For Mash Indication Following CDSCO Approval
Brief: Emcure Pharmaceuticals Says Kuber Jagdale, President, API Business, Superannuates
India's Emcure Pharma hits record high after Jefferies raises TP
Brief: Emcure Pharmaceuticals March-Quarter Consol Net Profit 2.43 Billion Rupees